HK1071845A1 - Therapeutic uses of dunaliella powder - Google Patents

Therapeutic uses of dunaliella powder

Info

Publication number
HK1071845A1
HK1071845A1 HK05103861.5A HK05103861A HK1071845A1 HK 1071845 A1 HK1071845 A1 HK 1071845A1 HK 05103861 A HK05103861 A HK 05103861A HK 1071845 A1 HK1071845 A1 HK 1071845A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic uses
dunaliella powder
subject
powder
dunaliella
Prior art date
Application number
HK05103861.5A
Other languages
English (en)
Inventor
Aviv Shaish
Dror Harats
Original Assignee
Nikken Sohonsha Corp
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Sohonsha Corp, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Nikken Sohonsha Corp
Publication of HK1071845A1 publication Critical patent/HK1071845A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK05103861.5A 2003-09-24 2005-05-09 Therapeutic uses of dunaliella powder HK1071845A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/668,601 US7264813B2 (en) 2003-09-24 2003-09-24 Therapeutic uses of Dunaliella powder

Publications (1)

Publication Number Publication Date
HK1071845A1 true HK1071845A1 (en) 2005-08-05

Family

ID=34313520

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103861.5A HK1071845A1 (en) 2003-09-24 2005-05-09 Therapeutic uses of dunaliella powder

Country Status (6)

Country Link
US (3) US7264813B2 (ja)
EP (2) EP1522310B1 (ja)
JP (5) JP5020463B2 (ja)
AT (1) ATE548046T1 (ja)
HK (1) HK1071845A1 (ja)
IL (1) IL162987A (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210917A (ja) * 2006-02-08 2007-08-23 Kochi Univ 脂肪細胞縮小化剤、医薬品及び飲食品
CA2644423A1 (en) * 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
JP2008222555A (ja) * 2007-03-08 2008-09-25 Nagasakiken Koritsu Daigaku Hojin アディポネクチン受容体発現増加剤
WO2009105048A2 (fr) * 2008-02-19 2009-08-27 Rached Smida Nouvelles applications du hdl reconstitué
EP2296682B8 (en) 2008-04-29 2018-07-04 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
US20100303989A1 (en) 2008-10-14 2010-12-02 Solazyme, Inc. Microalgal Flour
JP5733592B2 (ja) * 2008-10-20 2015-06-10 株式会社日健総本社 脂質異常治療薬の副作用防止物質
WO2010102056A1 (en) * 2009-03-03 2010-09-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
EP2509611B1 (en) * 2009-12-10 2016-03-02 Nikken Sohonsha Corporation Crude dunaliella powder for use in treating psoriasis
EP2543072B1 (en) 2010-03-02 2021-10-06 Vishay-Siliconix Structures and methods of fabricating dual gate devices
US10098371B2 (en) 2013-01-28 2018-10-16 Solazyme Roquette Nutritionals, LLC Microalgal flour
FR3009619B1 (fr) 2013-08-07 2017-12-29 Roquette Freres Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee
GB201718822D0 (en) 2017-11-14 2017-12-27 Univ Greenwich Production of dunaliella
JP6947665B2 (ja) * 2018-03-13 2021-10-13 アイカ工業株式会社 光硬化性粘着樹脂組成物
WO2020202152A1 (en) * 2019-04-01 2020-10-08 Tel Hashomer Medical Research Infrastructure And Services Ltd. Dunaliella alga preparation for prevention and/or treatment of a neurodegenerative disease, a disorder associated with protein misfolding and cognitive decline

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199895A (en) 1977-05-25 1980-04-29 Yeda Research And Development Co. Ltd. Production of glycerol, carotenes and algae meal
USPP4511P (en) 1978-06-26 1980-03-18 Yeda Research & Development Co. Ltd. Alga strain
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
IL87260A (en) * 1988-02-25 1991-12-15 Tanaka Yoshio Encapsulated food containing dunaliella algae and its production
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5219888A (en) 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
WO1993024454A1 (en) 1992-06-04 1993-12-09 Betatene Limited High cis beta-carotene composition
US6262109B1 (en) * 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
DK0859608T3 (da) 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
AU7074496A (en) * 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
IL119224A (en) 1996-09-09 2002-11-10 Hadasit Med Res Service Medicament for protection from effects of irradiation
JP3037628B2 (ja) * 1997-03-06 2000-04-24 マイクロアルジェコーポレーション株式会社 健康補助食品用軟カプセルの製法
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
EP1144997A3 (en) 1998-03-30 2002-08-28 The Regents of the University of California Methods and compounds for modulating nuclear receptor activity
ATE318138T1 (de) 1998-06-30 2006-03-15 Takeda Pharmaceutical Pharmazeutisches mittel zur behandlung von diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
PL348503A1 (en) * 1998-12-23 2002-05-20 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
WO2001019770A2 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
WO2003027090A2 (en) 2001-09-25 2003-04-03 Smithkline Beecham Corporation Bicyclic heterocycles as rxr ligands
IN189624B (ja) * 2001-10-23 2003-03-29 Ajanta Pharma Ltd
JP3978582B2 (ja) * 2001-12-19 2007-09-19 株式会社日健総本社 カロチノイドの製造方法
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Also Published As

Publication number Publication date
JP6490782B2 (ja) 2019-03-27
JP5356946B2 (ja) 2013-12-04
ATE548046T1 (de) 2012-03-15
JP2005097255A (ja) 2005-04-14
JP5020463B2 (ja) 2012-09-05
US20050063991A1 (en) 2005-03-24
EP1522310B1 (en) 2012-03-07
US20080019997A1 (en) 2008-01-24
US20100221348A1 (en) 2010-09-02
JP2016147916A (ja) 2016-08-18
JP6321074B2 (ja) 2018-05-09
US7763255B2 (en) 2010-07-27
JP2018035200A (ja) 2018-03-08
US8343549B2 (en) 2013-01-01
US7264813B2 (en) 2007-09-04
JP2013177457A (ja) 2013-09-09
IL162987A (en) 2013-06-27
EP2269620A1 (en) 2011-01-05
EP1522310A1 (en) 2005-04-13
JP2009256392A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
HK1071845A1 (en) Therapeutic uses of dunaliella powder
HK1100353A1 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
WO2007124461A3 (en) Glp-1 compounds
WO2007014094A3 (en) Method of and system for predicting dose delivery
IL176259A0 (en) Compositions and methods for treating diabetes
EP1771188A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS, INSULINED DISEASES AND HYPERCHOLESTERINEMIA
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
HK1076721A1 (en) A chinese traditional medical composition for treating diabetes and method for preparing the same
EP1774029A4 (en) METHOD FOR DETECTING THE RISKS OF NON-INSULIN-DEPENDENT DIABETES AND FOR TREATING THIS TYPE OF DIABETES
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
WO2006107411A3 (en) Formulations containing fenofibrate and surfacant mixture
EP1579213A4 (en) DIAGNOSTIC PROCEDURE, TREATMENT AND USEFUL MEDICINES FOR SUFFERING BY MODULATION OF THE ACTIVIN BETA C MIRROR
IL165304A0 (en) Method of treating diabetes
AU2003236521A8 (en) Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
EP1624954A4 (en) PLATFORM APPARATUS, COLUMN HAVING THE APPARATUS AND METHOD OF ASSEMBLY AND USE THEREOF
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
EP1613318A4 (en) COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES
ZA200705470B (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
AU2003269105A8 (en) Perfluorinated fatty acids for the treatment of obesity, diabetes, hyperlipidaemia, cancer and inflammation
WO2005089259A3 (en) Method for treating aortic stenosis with non-antibacterial tetracycline formulations
EP1734963A4 (en) METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
AU2011213703B2 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
AU2003240254A1 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
GB2433935B (en) Compounds for treating diabetes and related disorders

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240811